Rajesha Rupaimoole

List of Publications by Year
in descending order

62 papers	9,567 citations	71102 41 h-index	114465 63 g-index
63 all docs	63 docs citations	63 times ranked	19124 citing authors

#	Article	IF	Citations
1	MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nature Reviews Drug Discovery, 2017, 16, 203-222.	46.4	3,558
2	Paraneoplastic Thrombocytosis in Ovarian Cancer. New England Journal of Medicine, 2012, 366, 610-618.	27.0	651
3	miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer Discovery, 2016, 6, 235-246.	9.4	554
4	Tumour angiogenesis regulation by the miR-200 family. Nature Communications, 2013, 4, 2427.	12.8	363
5	Integrated Analyses Identify a Master MicroRNA Regulatory Network for the Mesenchymal Subtype in Serous Ovarian Cancer. Cancer Cell, 2013, 23, 186-199.	16.8	340
6	Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Molecular Systems Biology, 2014, 10, 728.	7.2	255
7	Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread. Cancer Cell, 2014, 26, 77-91.	16.8	252
8	Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. Nature Communications, 2014, 5, 5203.	12.8	195
9	Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nature Communications, 2017, 8, 310.	12.8	169
10	Autocrine Effects of Tumor-Derived Complement. Cell Reports, 2014, 6, 1085-1095.	6.4	164
11	Role of Focal Adhesion Kinase in Regulating YBâ€“1â€“Mediated Paclitaxel Resistance in Ovarian Cancer. Journal of the National Cancer Institute, 2013, 105, 1485-1495.	6.3	151
12	Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nature Communications, 2014, 5, 5202.	12.8	151
13	FABP4 as a key determinant of metastatic potential of ovarian cancer. Nature Communications, 2018, 9, 2923.	12.8	151
14	Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. Clinical Cancer Research, 2017, 23, 2891-2904.	7.0	122
15	Yesâ€associated protein 1 and transcriptional coactivator with PDZâ€binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma. Hepatology, 2016, 63, 159-172.	7.3	115
16	Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. Cell Reports, 2015, 13, 2395-2402.	6.4	105
17	2â€²-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nature Communications, 2014, 5, 3459.	12.8	103
18	Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers. Journal of the National Cancer Institute, 2015, 107, .	6.3	102

#	Article	IF	Citations
19	FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. Journal of Clinical Investigation, 2016, 126, 1885-1896.	8.2	101
20	A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nature Communications, 2016, 7, 11169.	12.8	100
21	Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell, 2015, 28, 610-622.	16.8	94
22	<scp>MiR</scp>â€506 inhibits multiple targets in the epithelialâ€toâ€mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. Journal of Pathology, 2015, 235, 25-36.	4.5	94
23	Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene, 2016, 35, 4312-4320.	5.9	83
24	MicroRNA therapeutics: principles, expectations, and challenges. Chinese Journal of Cancer, 2011, 30, 368-370.	4.9	82
25	Molecular Biomarkers of Residual Disease after Surgical Debulking of High-Grade Serous Ovarian Cancer. Clinical Cancer Research, 2014, 20, 3280-3288.	7.0	80
26	Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 5331-5336.	7.1	79
27	Therapeutic Silencing of KRAS Using Systemically Delivered siRNAs. Molecular Cancer Therapeutics, 2014, 13, 2876-2885.	4.1	77
28	Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis. Oncogene, 2016, 35, 2390-2397.	5.9	71
29	Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer. Clinical Cancer Research, 2016, 22, 1713-1724.	7.0	69
30	Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. Cancer Research, 2018, 78, 3233-3242.	0.9	69
31	Personalized RNA Medicine for Pancreatic Cancer. Clinical Cancer Research, 2018, 24, 1734-1747.	7.0	67
32	Biologic Effects of Dopamine on Tumor Vasculature in Ovarian Carcinoma. Neoplasia, 2013, 15, 502-IN15.	5.3	66
33	Complement Component 3 Is Regulated by TWIST1 and Mediates Epithelialâ€“Mesenchymal Transition. Journal of Immunology, 2016, 196, 1412-1418.	0.8	66
34	A new method for stranded whole transcriptome RNA-seq. Methods, 2013, 63, 126-134.	3.8	59
35	Notch3 Pathway Alterations in Ovarian Cancer. Cancer Research, 2014, 74, 3282-3293.	0.9	59
36	ATP11B mediates platinum resistance in ovarian cancer. Journal of Clinical Investigation, 2013, 123, 2119-2130.	8.2	56

#	Article	IF	Citations
37	Role of Increased n-acetylaspartate Levels in Cancer. Journal of the National Cancer Institute, 2016, 108, djv426.	6.3	51
38	Role of Platelet-Derived Tgfî²1 in the Progression of Ovarian Cancer. Clinical Cancer Research, 2017, 23, 5611-5621.	7.0	51
39	The ZNF304-integrin axis protects against anoikis in cancer. Nature Communications, 2015, 6, 7351.	12.8	48
40	Pan-cancer genomic analysis links 3â€™UTR DNA methylation with increased gene expression in T cells. EBioMedicine, 2019, 43, 127-137.	6.1	48
41	Copy Number Gain of hsa-miR-569 at 3q26.2 Leads to Loss of TP53INP1 and Aggressiveness of Epithelial Cancers. Cancer Cell, 2014, 26, 863-879.	16.8	46
42	Antagonism of Tumoral Prolactin Receptor Promotes Autophagy-Related Cell Death. Cell Reports, 2014, 7, 488-500.	6.4	43
43	Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth. Molecular Cancer Therapeutics, 2016, 15, 1344-1352.	4.1	41
44	Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. Oncogene, 2016, 35, 691-701.	5.9	40
45	XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. Clinical Cancer Research, 2015, 21, 3286-3297.	7.0	37
46	Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer. Cancer Biology and Therapy, 2014, 15, 1061-1067.	3.4	34
47	Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Reports, 2017, 21, 2785-2795.	6.4	32
48	Metronomic Docetaxel in PRINT Nanoparticles and EZH2 Silencing Have Synergistic Antitumor Effect in Ovarian Cancer. Molecular Cancer Therapeutics, 2014, 13, 1750-1757.	4.1	31
49	Cross-talk between EphA2 and BRaf/CRaf Is a Key Determinant of Response to Dasatinib. Clinical Cancer Research, 2014, 20, 1846-1855.	7.0	25
50	Developing hyperpolarized silicon particles forin vivoMRI targeting of ovarian cancer. Journal of Medical Imaging, 2016, 3, 036001.	1.5	24
51	ADH1B promotes mesothelial clearance and ovarian cancer infiltration. Oncotarget, 2018, 9, 25115-25126.	1.8	24
52	PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. Molecular Cancer Therapeutics, 2019, 18, 162-172.	4.1	23
53	PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. Molecular Cancer Therapeutics, 2015, 14, 1466-1475.	4.1	20
54	C-terminal fragment of transforming growth factor beta-induced protein (TGFBIp) is required for apoptosis in human osteosarcoma cells. Matrix Biology, 2009, 28, 347-353.	3.6	19

#	Article	IF	Citations
55	A High-Throughput Small Molecule Screen Identifies Ouabain as Synergistic with miR-34a in Killing Lung Cancer Cells. IScience, 2020, 23, 100878.	4.1	13
56	Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. JCI Insight, 2016, 1, e87754.	5.0	11
57	A role for miR-34 in colon cancer stem cell homeostasis. Stem Cell Investigation, 2016, 3, 42-42.	3.0	9
58	Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. Journal of the National Cancer Institute, 2017, 109, .	6.3	9
59	Macrophage TGF-<i>Î²</i>1 and the Proapoptotic Extracellular Matrix Protein BIGH3 Induce Renal Cell Apoptosis in Prediabetic and Diabetic Conditions. International Journal of Clinical Medicine, 2016, 07, 496-510.	0.2	8
60	Genome-wide perturbations by miRNAs map onto functional cellular pathways, identifying regulators of chromatin modifiers. Npj Systems Biology and Applications, 2015, 1, 15001.	3.0	3
61	Complement Component 3 (C3) Is Transcriptionally Regulated By TWIST1. Blood, 2013, 122, 1046-1046.	1.4	1
62	MicroRNA therapeutics: principles, expectations, and challenges. Chinese Journal of Cancer, 2011, 30, 368-370.	4.9	1